文献速递眼底病与葡萄膜炎

APE1氧化还原抑制剂通过抑制FGF2血管生成信号减轻病理性视网膜血管化

An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究在氧诱导视网膜病变(OIR)小鼠模型中评估APE1氧化还原抑制剂Refi-10对病理性视网膜新生血管(RNV)的治疗作用及机制。Refi-10显著减少病理性血管生成并改善RNV病变,机制上通过抑制APE1减轻炎症和血管生成,且不降低视网膜VEGF而通过抑制FGF2表达发挥作用。结果提名APE1和FGF2信号为有前景的治疗靶点,Refi-10可作为血管性视网膜病变的候选药物。

要点

  • Refi-10在OIR小鼠中显著减少病理性血管生成并改善RNV病变。
  • Refi-10不降低视网膜VEGF,而是通过抑制FGF2表达减轻RNV。
  • APE1和FGF2信号被提名为血管性视网膜病变的潜在治疗靶点。

核心结论

  • Refi-10通过抑制APE1氧化还原功能、下调FGF2表达来减轻病理性视网膜新生血管,不依赖降低VEGF。
  • APE1和FGF2信号是有前景的治疗靶点,Refi-10可作为血管性视网膜病变的候选药物,提供VEGF抑制的替代或互补策略。

研究设计与样本

  • 使用氧诱导视网膜病变(OIR)小鼠模型和APE1氧化还原抑制剂Refi-10研究APE1氧化还原功能在视网膜新生血管中的作用及Refi-10疗效。
  • 对OIR视网膜进行转录组分析,鉴定与RNV及Refi-10介导改善相关的促血管生成因子和通路。
  • 使用视网膜色素上皮(RPE)和人视网膜微血管内皮细胞(hRMECs)研究细胞机制及对Refi-10的反应。

主要发现

  • Refi-10显著减少病理性血管生成并改善RNV病变。
  • 机制研究表明Refi-10通过抑制APE1减轻炎症和血管生成。
  • Refi-10在OIR中不降低视网膜VEGF,而是通过抑制成纤维细胞生长因子2(FGF2)表达来减轻RNV。

临床怎么用

  • Refi-10可能作为血管性视网膜病变的候选药物,尤其针对抗VEGF抵抗或需减少反复眼内注射风险的情形。
  • APE1和FGF2信号可作为替代或互补于VEGF抑制的治疗靶点进行进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retinal neovascular (RNVs) diseases are major causes of visual loss. Current first-line therapies for RNV primarily target VEGF. However, intrinsic or acquired resistance to anti-VEGF therapy, along with the risks associated with repeated intraocular injections, underscores the need for alternative targets and new therapeutic strategies. Apurinic/apyrimidinic endonuclease 1 (APE1) regulates transcription factors implicated in RNV. The purpose of this study was to evaluate APE1 as a therapeutic target, assess the potential of its redox inhibitor, Refi-10, as a drug candidate for vascular retinopathies, and elucidate underlying mechanisms. METHODS: An oxygen-induced retinopathy (OIR) mouse model and the APE1 redox inhibitor Refi-10 were used to investigate the contribution of APE1 redox function in retinopathy neovascularization and assess the therapeutic efficacy of Refi-10. Transcriptomic analysis of OIR retinas identified pro-angiogenic factors and pathways associated with RNV and Refi-10-mediated improvement. Retinal pigment epithelium (RPE) and human retinal microvascular endothelial cells (hRMECs) were used to investigate cellular mechanisms and responses to Refi-10. RESULTS: Refi-10 significantly reduced pathological angiogenesis and ameliorated RNV disease. Mechanistic studies showed that Refi-10 attenuated inflammation and angiogenesis via APE1 inhibition. Notably, Refi-10 did not decrease retinal VEGF in OIR but mitigated RNV by suppressing fibroblast growth factor 2 (FGF2) expression. CONCLUSIONS: These findings nominate APE1 and FGF2 signaling as promising therapeutic targets, and show that Refi-10 holds potential as a drug candidate for vascular retinopathies, offering an alternative or complementary approach to VEGF inhibition.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Yan C, Fu Q, Wang J, et al. An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling. Invest Ophthalmol Vis Sci. 2026. PMID: 41860321. doi:10.1167/iovs.67.3.47

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。